The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Recent advances in the field of clinical biomarkers suggest that quantification of serum proteins could play an important role in the diagnosis, classification, prognosis, and treatment response of smoking-related parenchymal lung diseases. COPD and idiopathic pulmonary fibrosis (IPF), two common chronic progressive parenchymal lung diseases, share cigarette smoke exposure as a common dominant risk factor for their development. We have recently shown that COPD and interstitial lung disease may represent distinct outcomes of chronic tobacco use, whereas others have demonstrated that both diseases coexist in some individuals. In this perspective, we examine the potential role of peripheral blood biomarkers in predicting which individuals will develop COPD or IPF, as well as their usefulness in tracking disease progression and exacerbations. Additionally, given the current lack of sensitive and effective metrics to determine an individual's response to treatment, we evaluate the potential role of biomarkers as surrogate markers of clinical outcomes. Finally, we examine the possibility that changes in levels of select protein biomarkers can provide mechanistic insight into the common origins and unique individual susceptibilities that lead to the development of smoking-related parenchymal lung diseases. This discussion is framed by a consideration of the properties of ideal biomarkers for different clinical and research purposes and the best uses for those biomarkers that have already been proposed and investigated.

[1]  I. Rosas,et al.  Subclinical interstitial lung disease: why you should care. , 2012, American journal of respiratory and critical care medicine.

[2]  N. Kaminski,et al.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. , 2012, American journal of respiratory and critical care medicine.

[3]  L. Edwards,et al.  Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[4]  R. Kalhan,et al.  Biomarkers in chronic obstructive pulmonary disease. , 2012, Translational research : the journal of laboratory and clinical medicine.

[5]  Imre Noth,et al.  Peripheral blood biomarkers in idiopathic pulmonary fibrosis. , 2012, Translational research : the journal of laboratory and clinical medicine.

[6]  K. Kostikas,et al.  Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. , 2012, Chest.

[7]  J. Maurer.  Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Identification of Biologic Clusters and Their Biomarkers , 2012 .

[8]  Jianhua Yao,et al.  Automated quantification of high-resolution CT scan findings in individuals at risk for pulmonary fibrosis. , 2011, Chest.

[9]  K. Chida,et al.  Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). , 2011, Clinica chimica acta; international journal of clinical chemistry.

[10]  John P A Ioannidis,et al.  Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study , 2011, BMJ : British Medical Journal.

[11]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[12]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[13]  A. Diaz de Leon,et al.  Quantification of regional interstitial lung disease from CT-derived fractional tissue volume: a lung tissue research consortium study. , 2011, Academic radiology.

[14]  L. Edwards,et al.  Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. , 2011, American journal of respiratory and critical care medicine.

[15]  T. King.  Smoking and subclinical interstitial lung disease. , 2011, The New England journal of medicine.

[16]  Katherine P Andriole,et al.  Lung volumes and emphysema in smokers with interstitial lung abnormalities. , 2011, The New England journal of medicine.

[17]  E. Silverman,et al.  Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. , 2011, American journal of respiratory cell and molecular biology.

[18]  H. Collard,et al.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[19]  B. Nordestgaard,et al.  C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach , 2010, Thorax.

[20]  S. Sone,et al.  The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. , 2010, Respiratory medicine.

[21]  K. Chida,et al.  Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. , 2010, Respiratory medicine.

[22]  H. Collard,et al.  Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[23]  J. Soriano,et al.  Systemic inflammation in chronic obstructive pulmonary disease: a population-based study , 2010, Respiratory research.

[24]  Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. , 2010, Annals of epidemiology.

[25]  N. Kaminski,et al.  CD28 Down-Regulation on Circulating CD4 T-Cells Is Associated with Poor Prognoses of Patients with Idiopathic Pulmonary Fibrosis , 2010, PloS one.

[26]  Raúl San José Estépar,et al.  Identification of early interstitial lung disease in smokers from the COPDGene Study. , 2010, Academic radiology.

[27]  D. Sin,et al.  Serum Surfactant Protein D during Acute Exacerbations of Chronic Obstructive Pulmonary Disease , 2010, Disease markers.

[28]  P. Zanen,et al.  Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. , 2009, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[29]  D. Sin,et al.  Biomarkers in chronic obstructive pulmonary disease. , 2009, Proceedings of the American Thoracic Society.

[30]  Janet S. Lee,et al.  The Influence of Radiographic Phenotype and Smoking Status on Peripheral Blood Biomarker Patterns in Chronic Obstructive Pulmonary Disease , 2009, PloS one.

[31]  M. Humbert,et al.  Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome , 2009, European Respiratory Journal.

[32]  K. Brown,et al.  Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. , 2009, Chest.

[33]  M. Olschewski,et al.  Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[34]  P. O'Byrne,et al.  Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[35]  L. Edwards,et al.  Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD , 2009, European Respiratory Journal.

[36]  D. Morrow,et al.  The future of biomarkers in the management of patients with acute coronary syndromes , 2008, Current opinion in cardiology.

[37]  M Cazzola,et al.  Outcomes for COPD pharmacological trials: From lung function to biomarkers. , 2008, Revista portuguesa de pneumologia.

[38]  B. Celli,et al.  C-reactive protein levels and survival in patients with moderate to very severe COPD. , 2008, Chest.

[39]  M. Dahl.  Biomarkers for chronic obstructive pulmonary disease: surfactant protein D and C-reactive protein. , 2008, American journal of respiratory and critical care medicine.

[40]  D. Sin,et al.  The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[41]  I. Adcock,et al.  Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction , 2008, European Respiratory Journal.

[42]  T. Shim,et al.  Is metalloproteinase-7 specific for idiopathic pulmonary fibrosis? , 2008, Chest.

[43]  Naftali Kaminski,et al.  MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis , 2008, PLoS medicine.

[44]  M. Pistolesi,et al.  Outcomes for COPD pharmacological trials: from lung function to biomarkers , 2008, European Respiratory Journal.

[45]  A. Jaffe,et al.  National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure. , 2007, Clinical biochemistry.

[46]  F. Sciurba,et al.  MMP 1 and MMP 7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis , 2008 .

[47]  A. Jaffe,et al.  National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. , 2008, Circulation.

[48]  D. Sin,et al.  Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study , 2007, BMC pulmonary medicine.

[49]  R. Stockley.  Biomarkers in COPD: time for a deep breath , 2007, Thorax.

[50]  Bartolome Celli,et al.  Profiling serum biomarkers in patients with COPD: associations with clinical parameters , 2007, Thorax.

[51]  A. Jaffe,et al.  National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. , 2007, Clinical chemistry.

[52]  S. Bojesen,et al.  C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[53]  G. Donaldson.  C-reactive protein: does it predict mortality? , 2007, American journal of respiratory and critical care medicine.

[54]  John R Hurst,et al.  Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[55]  D. Postma,et al.  Pulmonary biomarkers in chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[56]  M. Selman,et al.  Matrix metalloproteases in aberrant fibrotic tissue remodeling. , 2006, Proceedings of the American Thoracic Society.

[57]  B. Celli,et al.  C-reactive protein levels and clinically important predictive outcomes in stable COPD patients , 2006, European Respiratory Journal.

[58]  M. Nishimura,et al.  Prognostic value of circulating KL‐6 in idiopathic pulmonary fibrosis , 2006, Respirology.

[59]  K. Kashiwabara.  Characteristics and disease activity of early interstitial lung disease in subjects with true parenchymal abnormalities in the posterior subpleural aspect of the lung. , 2006, Chest.

[60]  J. Soriano,et al.  C-reactive protein in patients with COPD, control smokers and non-smokers , 2005, Thorax.

[61]  K. Flaherty,et al.  Smoking: an injury with many lung manifestations. , 2005, American journal of respiratory and critical care medicine.

[62]  P. Brillet,et al.  Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity , 2005, European Respiratory Journal.

[63]  D. Ransohoff.  Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.

[64]  N. Kohno.  [Sialylated carbohydrate antigen KL-6]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[65]  A Senthilselvan,et al.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.

[66]  D. Ransohoff.  Developing Molecular Biomarkers for Cancer , 2003, Science.

[67]  David F Ransohoff,et al.  Cancer. Developing molecular biomarkers for cancer. , 2003, Science.

[68]  Mark Schena,et al.  Trends in microarray analysis , 2003, Nature Medicine.

[69]  G. Hunninghake,et al.  Serum surfactant proteins‐A and ‐D as biomarkers in idiopathic pulmonary fibrosis , 2002, European Respiratory Journal.

[70]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[71]  S. Abe,et al.  Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. , 2000, American journal of respiratory and critical care medicine.

[72]  J A Waldron,et al.  Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. , 1997, American journal of respiratory and critical care medicine.

[73]  N. Kohno,et al.  New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. , 1989, Chest.